Cingulate Advances ADHD Treatment Toward 2026 FDA Decision with Key Milestones
Cingulate Inc. progresses toward potential 2026 commercial launch of its ADHD treatment CTx-1301 following FDA acceptance of its New Drug Application and positive pediatric trial results, addressing a large market with unmet needs.
Stonegate Capital Partners has updated its coverage of Cingulate Inc. (NASDAQ: CING), highlighting the company's third-quarter 2025 progress toward transforming its lead candidate, CTx-1301, into a commercial franchise for attention-deficit/hyperactivity disorder. The update follows several key developments, including U.S. Food and Drug Administration acceptance of the CTx-1301 New Drug Application with a Prescription Drug User Fee Act target action date of May 31, 2026. This regulatory milestone, achieved under the 505(b)(2) pathway, positions the company for a potential launch in 2026, subject to approval, in the substantial U.S. ADHD market.
The importance of this advancement lies in CTx-1301's profile and the market need it aims to address. The NDA submission includes adult and pediatric Phase 3 data demonstrating rapid onset and full-day symptom control with a safety profile consistent with existing long-acting methylphenidate products. Positive pediatric Phase 3 data specifically showed rapid onset and entire active-day symptom control. The therapy utilizes Cingulate's proprietary Precision Timed Release platform to deliver three timed releases of dexmethylphenidate in a once-daily tablet. This technical approach is designed to meet unmet patient needs for treatments that work quickly and last throughout the day, a significant consideration in ADHD management.
Financially, the company is investing heavily in this late-stage push. Third-quarter 2025 research and development expenses rose to $2.8 million from $1.4 million year-over-year, while general and administrative costs increased to $3.1 million from $1.9 million, driven by Phase 3 activities, NDA support, and commercial planning. The net loss widened to $7.3 million from $4.1 million in the third quarter of 2024. As of the quarter's end, Cingulate reported $6.1 million in cash and cash equivalents and approximately $1.6 million in working capital. Post-quarter, the company secured a $6.0 million unsecured promissory note, extending its cash runway into the second quarter of 2026 as management evaluates additional financing options for launch and early commercialization.
Operational preparations are advancing in parallel. Cingulate has executed an exclusive commercial supply agreement with Bend Bio Sciences to secure U.S. manufacturing capacity ahead of a potential launch. The company has also strengthened its leadership team, appointing industry veteran Bryan Downey as Chief Commercial Officer to lead launch preparation and go-to-market strategy. He will oversee the execution of the company's partnership with Indegene, focusing on market access and commercial deployment. Management continuity is provided by Interim CEO and CFO Jennifer Callahan and Executive Chairman Jay Roberts through the FDA review period.
The broader strategic implication involves Cingulate's pipeline and platform. Beyond CTx-1301, the company is advancing CTx-1302 for patients who may respond better to amphetamine-based stimulants and progressing CTx-2103 for anxiety disorders. These programs underscore the potential scalability of the Precision Timed Release platform across large neuropsychiatric indications. Stonegate Capital Partners' valuation analysis, employing a discounted cash flow model, suggests a valuation range for Cingulate of $15.29 to $31.44, with a midpoint of $21.86. The firm provides investor relations and research services, with its affiliate, Stonegate Capital Markets, offering investment banking. More information on Stonegate Capital Partners is available at https://www.stonegateinc.com.